To main content To main navigation

Hilde Jalving

Internist-oncologist Profile

Internist-oncologist

Contact information

Discover our research

Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol

2024, The Lancet Regional Health - Europe

Everolimus decreases [U-13C]glucose utilization by pyruvate carboxylase in breast cancer cells in vitro and in vivo.

2024, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

All publications

- Behandeling melanoom in stadium III/IVHilde Jalving (Invited speaker) 6-Apr-2024 Professional or public presentation > Professional
- Nadina Studie update - (neo )adjuvante behandeling van melanoomHilde Jalving (Invited speaker) 6-Apr-2024 Professional or public presentation > Professional
- (Neo-) Adjuvante behandeling, systeemtherapie en bijwerkingenHilde Jalving (Invited speaker) 6-Mar-2024 Professional or public presentation > Popular
- MEDtalks Melanoomupdate 2024Hilde Jalving (Speaker) 10-Jan-2024 Professional or public presentation > Professional
- WIN-O Multidisciplinair symposium melanoom en niet-melanoom huidkanker 2023Hilde Jalving (Contributor) 27-Nov-2023 Organising and contributing to an event > Academic
All activities
- Young Investigator Grant DutchHilde Jalving, 2017 Academic
All prizes

Contact